NASDAQ:NTLA Intellia Therapeutics Q1 2026 Earnings Report $12.16 -0.22 (-1.74%) As of 12:09 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Intellia Therapeutics EPS ResultsActual EPS-$0.81Consensus EPS -$0.92Beat/MissBeat by +$0.11One Year Ago EPS-$1.10Intellia Therapeutics Revenue ResultsActual Revenue$15.05 millionExpected Revenue$13.81 millionBeat/MissBeat by +$1.24 millionYoY Revenue GrowthN/AIntellia Therapeutics Announcement DetailsQuarterQ1 2026Date5/11/2026TimeBefore Market OpensConference Call DateMonday, May 11, 2026Conference Call Time7:30AM ETUpcoming EarningsIntellia Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Intellia Therapeutics Earnings HeadlinesBarclays Initiates Intellia Therapeutics at Underweight With $8 Price TargetOctober 7 at 3:15 AM | finance.yahoo.comWells Fargo Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)October 6 at 12:11 PM | theglobeandmail.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.October 7 at 1:00 AM | Banyan Hill Publishing (Ad)Cathie Wood's Ark Invest weekly recap: loads up on Nvidia, Intellia; pares AMDOctober 5 at 8:31 AM | msn.comIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | globenewswire.comShort interest alert: Most and least shorted sub-$2B healthcare stocks in Sep. 2026October 2, 2026 | msn.comSee More Intellia Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Intellia Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Intellia Therapeutics and other key companies, straight to your email. Email Address About Intellia TherapeuticsIntellia Therapeutics (NASDAQ:NTLA) is a biotechnology company focused on developing genome-editing therapies using CRISPR/Cas9 technology. The company is working to create treatments that can directly modify disease-causing genes, including through in vivo approaches in which the editing machinery is delivered into a patient’s body. Its pipeline has included NTLA-2001, an investigational therapy designed to reduce production of transthyretin for the treatment of transthyretin amyloidosis, and NTLA-2002, an investigational program targeting kallikrein for hereditary angioedema. Intellia has also pursued additional research programs in areas such as genetic liver diseases and other serious conditions. Founded in 2014, Intellia was established by a group of scientists and entrepreneurs, including CRISPR pioneer Jennifer Doudna. The company’s research and clinical-development activities have included collaborations and studies in the United States and other regions. John M. Leonard serves as president and chief executive officer, overseeing Intellia’s development of CRISPR-based medicines.View Intellia Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Wall Street Is Betting These 3 Beaten-Down Stocks Have More Room to RunLamb Weston’s Turnaround Is Starting to Look RealRPM International’s Dividend King Status Just Got StrongerAI Chip Demand Gives Linde a New Growth CatalystAllient’s Data Center and Defense Momentum Is Raising the StakesInvenTrust’s Sell-Off Opens a Potential Entry PointCuraleaf’s Higher Aurora Bid Raises the Stakes in Cannabis Consolidation Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
